The AGITG-sponsored, investigator-initiated CONTROL NETs is a clinical trial for the treatment of advanced pancreatic neuroendocrine tumours (pNETs) and midgut neuroendocrine tumours (mNETs). It is a non-comparative randomised open label parallel group phase II trial with 2:1 randomisation to PRRT/CAPTEM (experimental arm) vs. PRRT (mNETs control) and CAPTEM (pNETS control).
CONTROL NETs TR exploratory sub-study is a multi-omic assessment of MGMT as a biomarker to predict which patients will benefit from the addition of CAPTEM to PRRT, using samples gathered from participants in the CONTROL NETs trial.
Dr Ben Lawrence
Wednesday, 15 November
Session 2: New Concepts – Looking to our future, and Advanced Other AGITG Trials